Nurix Therapeutics Initiates Pivotal Phase 2 for Bexobrutideg in CLL, Reports Strong Data & Outlines 2026 Goals

summarizeSummary

Nurix Therapeutics announced the initiation of its pivotal Phase 2 DAYBreak CLL-201 study for bexobrutideg, reporting strong clinical data that positions it as a potential best-in-class BTK degrader, and outlined key pipeline and financial goals for 2026.

check_boxKey Events

• Pivotal Phase 2 Study Initiated

  Nurix commenced the DAYBreak CLL-201 pivotal Phase 2 study for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia (CLL), targeting accelerated approval.

• Strong Clinical Data for Bexobrutideg

  Updated Phase 1a data for bexobrutideg showed an 83% objective response rate and 22.1-month median progression-free survival in r/r CLL, outperforming a recently approved competitor in a more heavily pretreated patient group.

• Confirmatory Phase 3 Planned

  A randomized confirmatory Phase 3 trial (DAYBreak CLL-306) comparing bexobrutideg to pirtobrutinib is planned for 2026 to support full approval.

• Robust Financial Position

  The company reported a pro forma cash and investments balance of $663.8 million, bolstered by a $250 million follow-on offering in October 2025.

auto_awesomeAnalysis

This 8-K details significant progress for Nurix Therapeutics, particularly with its lead asset, bexobrutideg. The initiation of the pivotal DAYBreak CLL-201 Phase 2 study for accelerated approval in relapsed/refractory CLL is a major de-risking event. The reported Phase 1a data, showing an 83% objective response rate and 22.1-month median progression-free survival in a heavily pretreated population, compares favorably to a recently FDA-approved competitor, pirtobrutinib, suggesting a potential best-in-class profile. The company's plan to initiate a confirmatory Phase 3 trial against pirtobrutinib in 2026 further underscores its confidence. Additionally, positive Phase 1a data for the immuno-oncology asset NX-1607 and progress in partnered inflammation and immunology programs highlight a robust pipeline. A strong pro forma cash position of $663.8 million provides ample runway for these ambitious development plans. Investors should monitor the progress of the DAYBreak trials and further clinical data readouts.